February 16, 2018 / 4:58 PM / 8 months ago

BRIEF-Abbvie Announces New Phase 2 Data For Upadacitinib Showing Clinical And Endoscopic Outcomes In Crohn's Disease At 52 Weeks

Feb 16 (Reuters) - Abbvie Inc:

* ABBVIE ANNOUNCES NEW PHASE 2 DATA FOR UPADACITINIB SHOWING CLINICAL AND ENDOSCOPIC OUTCOMES IN CROHN'S DISEASE AT 52 WEEKS

* ABBVIE INC - ‍PHASE 3 TRIALS FOR UPADACITINIB IN CROHN'S DISEASE ARE ONGOING​

* ABBVIE - ‍OVERALL SAFETY PROFILE OF UPADACITINIB WAS CONSISTENT WITH THAT OBSERVED IN OTHER UPADACITINIB STUDIES, WITH NO NEW SAFETY SIGNALS DETECTED​

* ABBVIE - ‍MANY UPADACITINIB-TREATED PATIENTS WHO ACHIEVED CLINICAL RESPONSE§ AFTER 16-WEEK INDUCTION PHASE MAINTAINED RESPONSE AFTER 36-WEEK EXTENSION ​

* ABBVIE INC - ‍ 2 MALIGNANCIES OCCURRED IN 12 MG TWICE-DAILY ARM AND NO DEATHS OCCURRED IN CELEST STUDY​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below